Evogene (EVGN) Receivables (2011 - 2026)

Evogene has disclosed Receivables across 16 years of filings, most recently posting $384000.0 for Q2 2026.

• In Q2 2026, Receivables fell 69.08% year-over-year to $384000.0; the TTM figure through Jun 2026 stood at $384000.0 (down 69.08% YoY), while the FY2025 annual figure was $1.0 million, down 10.66% from the prior year.
• Receivables came in at $384000.0 for Q2 2026 at Evogene, up from $286000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.6 million in Q1 2025 to a low of $166000.0 in Q1 2022.
• Average Receivables over 5 years is $803611.1, with a median of $556500.0 recorded in 2022.
• Year-over-year, Receivables soared 389.8% in 2025 and sank 89.17% in 2026.
• Over 5 years, Receivables stood at $450000.0 in 2022, then climbed by 8.89% to $490000.0 in 2023, then surged by 133.67% to $1.1 million in 2024, then declined by 10.66% to $1.0 million in 2025, then slumped by 62.46% to $384000.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $384000.0 in Q2 2026, $286000.0 in Q1 2026, and $1.0 million in Q4 2025.